Xenios AG – a Fresenius Medical Care company – is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer the full range of heart and lung assist on one single platform: the Xenios console.

Xenios' dedication applies to the higher welfare of patients. The Novalung therapy can replace or supplement ventilation, which allows to prevent ventilation-associated lung damage. These minimally invasive therapies enable caregivers to keep lung failure patients awake, self-determined and mobile. End of 2016 Xenios has become part of the FME family, the worldwide market leader in renal support, and therefore forms a significant part of FME’s holistic multi-organ support.


European Respiratory Society (ERS) International Congress 2019

Sat, 28 Sep 2019 - Wed, 2 Oct 2019

Avenida Partenón 5
Madrid, Comunidad de Madrid 28042
32nd Annual Congress - ESICM LIVES 2019

Sat, 28 Sep 2019 - Wed, 2 Oct 2019

Messedamm 26 29
Berlin, 14055


ICU Management

Relaunch of the Xenios Website – Now harmonised with that of its parent, Fresenius Medical Care

2019 08 May

The Xenios AG, pioneer in extracorporeal heart and lung support, has restructured its website. Xenios AG has been part of the Fresenius Medical Care Group since 2016 and the new design also serves to bring the company visually in line with the brand image of its parent.   www.xenios-ag.com   With this newly structured website, the... Read more

ICU Management

Six Days Without a Lung – a Look into the Future of Medical Technology

2017 12 Apr

The dramatic story of Canadian Melissa Benoit, who lived for six days without a lung, shows a view of a new chapter in the history of medical technology. The novalung iLA membrane lung, which replaced the functions of the lung, is a product of XENIOS AG. As a strategic partner of XOR Labs in Toronto, both companies wanted to cooperate to revolutionize... Read more

Jobs not available


    Catalogue not available

Im Zukunftspark, 1
+49 7131 2706 422

White Papers - Case Studies

Not available



Not available

Lung failure therapies

Novalung is the world‘s first lung failure therapy platform, which competes favorably against one-product offerings. The Novalung product family enables therapies for lung failure that are adapted to specific indications. In addition, Novalung products’ smaller cannulas lower the threshold for adoption. In short, Novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The Novalung platform performs any level of CO2 removal and oxygenation in acute respiratory failure / AECOPD.

Medos has been making German medical technology history since 1987, for the benefit of cardiac surgeons, perfusionists and patients. Whether aortic valve replacement or bypass surgery, almost all cardiac surgery procedures can be performed effectively using Medos products. Upon the acquisition of Medos by Novalung's owners the Medos blood pump technology allowed to create cardiac assist for Xenios' state-of-the-art minimally invasive therapy portfolio.

The Xenios tubing set configurator guides you through the process of creating your own individual Medos tubing